Curon Announces $149.5 Million Deal for China Rights to Lymphoma Drug
October 12, 2020 at 07:47 AM EDT
Curon Biopharma, a Shanghai clinical-stage in-licensing company, acquired China rights to Tenalisib, a dual PI3K delta and gamma inhibitor, from Rhizen Pharma of Switzerland . Rhizen will receive upfront and milestone payments worth up to $149.5 million, plus royalties. Tenalisib is in US Phase II trials for lymphoma. In 2018, Curon raised $150 million in a Series A financing led by 6 Dimensions Capital, Boyu Capital, and Temasek. The company pledged to develop next-gen cancer immunotherapies for patients. More details.... Share this with colleagues: // //
